---
title: "Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Pharmacodynamics"
description: "Formulary evidence on Lorundrostat (MLS-101, MT-4129) in Hypertension, in combination with other antihypertensive drugs: Pharmacodynamics. Topics: Plasma aldosterone suppression after single and multiple doses in healthy participants; Aldosterone rebound after discontinuation in healthy participants; Basal and cosyntropin-stimulated cortisol in healthy participants; Plasma renin activity, 11-deoxycorticosterone, serum potassium, and natriuresis in healthy participants; 7 further topics. 11 evidence topics quoted from 7 sources."
canonical: "https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description/pharmacodynamics"
published: "2026-11-18T10:43:00-05:00"
modified: "2026-11-18T10:43:00-05:00"
---

# Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Pharmacodynamics

<a id="heading-2.1.2.6.2"></a>

## 2.1.2.6.2 Pharmacodynamics

<a id="topic-2.1.2.6.2-1"></a>

### Plasma aldosterone suppression after single and multiple doses in healthy participants

> “Single doses of lorundrostat, ranging from 10 to 800 mg reduced the AUC0–24 for PAC in a dose‐dependent manner, with statistically significant decreases ranging from 36% to 77% vs. placebo (Figure 2b; Table S5) without effecting cortisol (Figure 2c).”
> “PAC (AUC0–24) was reduced by up to 40% with single 100‐ to 200‐mg doses and up to 70% with single 400‐ to 800‐mg doses.”
> “At the lower dose levels (lorundrostat 5–50 mg), the PAC returned to values near baseline within 24 h post‐dose. At the higher dose levels (lorundrostat 100–800 mg), the reduction of PAC was sustained until 24 h post‐dose.”
> “Consistent with the SAD cohorts, multiple‐dose lorundrostat data demonstrated that for all dose levels tested, PAC decreased in an apparent dose‐dependent manner between 2 and 12 h post‐dose on Day 7 (Figure 2d).”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.2-2"></a>

### Aldosterone rebound after discontinuation in healthy participants

> “From 24 h after the last dose on Day 7, a clear rebound in PAC ranging from 73% to 163% compared with placebo was observed at all multiple‐dose levels of lorundrostat. These increases were sustained at least until Day 10, 3 days after the last dose.”
> “From Day 7 to Day 9, clear reductions in the urinary log10 (10 × Na+/K+) ratio were observed, suggesting a rebound effect for the sodium/potassium ratio as well.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.2-3"></a>

### Basal and cosyntropin-stimulated cortisol in healthy participants

> “During non‐ACTH challenge conditions, no relevant changes from baseline were observed for serum cortisol concentrations and plasma 11‐deoxycortisol concentrations during multiple dosing of lorundrostat. At all multiple‐dose levels, lorundrostat completely blunted the ACTH‐stimulated aldosterone response on Day 6 compared with placebo, while there was no effect on the cortisol response.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.2-4"></a>

### Plasma renin activity, 11-deoxycorticosterone, serum potassium, and natriuresis in healthy participants

> “Once‐daily administration of lorundrostat at doses ranging from 40 to 360 mg increased plasma renin activity and serum 11‐DOC compared with placebo (Figure 3a,b). Elevations in serum potassium concentrations due to lorundrostat‐mediated reductions in PAC were mild and seen across all doses tested (Figure 3c). These effects declined during the washout period.”
> “Urine sodium and urinary log10 (10 × Na+/K+) ratio were increased at all dose levels tested in the SAD, consistent with reduced aldosterone signaling (Figure 3d).”
> “Within 2 days of initiation of lorundrostat treatment, serum potassium rose in all three dose cohorts (part 2) by group mean values ranging from 0.28 to 0.38 mmol/L and remained elevated throughout the remainder of the 7 days of treatment.”
> “Given that the PD effects on renal electrolyte regulation were near maximum at 120 mg daily and the excessive 11‐DOC accumulation observed at dose of 360 mg once daily, the data suggest that the dose selection for the treatment of hypertension should avoid the higher dose level and focus on doses up to 120 mg daily.”

Source: [Shimizu et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11329366/)

<a id="topic-2.1.2.6.2-5"></a>

### Aldosterone reduction in participants with hypertension: company summary

> “Lorundrostat has 374-fold selectivity for aldosterone-synthase inhibition versus cortisol-synthase inhibition in vitro, has an observed half-life of 10-12 hours and demonstrated a 40-70% reduction in plasma aldosterone concentration in participants with hypertension.”

Source: [Mineralys Therapeutics third quarter 2026 results announcement (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/127/mineralys-therapeutics-reports-third-quarter-2026-financial)

<a id="topic-2.1.2.6.2-6"></a>

### Serum aldosterone, plasma renin activity, and cortisol in uncontrolled hypertension: Target-HTN

> “Lorundrostat resulted in reductions in serum aldosterone at all doses, whereas the cohort 1 placebo group saw an increase in mean serum aldosterone level of 0.14 (SD, 3.68) ng/dL. The 12.5-mg, 50-mg, and 100-mg once-daily doses in cohort 1 reduced mean serum aldosterone by 1.05 (SD, 4.33) ng/dL, 2.56 (SD, 3.72) ng/dL, and 2.88 (SD, 4.44) ng/dL, respectively.”
> “Anticipated increases in PRA were observed ranging between 0.78 (SD, 3.44) ng/mL/h to 4.65 (SD, 11.27) ng/mL/h in cohort 1, and there were small increases in serum cortisol”

Source: [Laffin et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10493865/)

<a id="topic-2.1.2.6.2-7"></a>

### Serum aldosterone and plasma renin activity in hypertension with chronic kidney disease: Explore-CKD

> “The geometric mean serum aldosterone level decreased by 41.5% during treatment with lorundrostat and increased by 1.8% during placebo treatment. The geometric mean plasma renin activity increased by 75.2% with lorundrostat and 4.2% with placebo. The geometric mean aldosterone-to-renin ratio decreased by 67.2% during treatment with lorundrostat and by 5.8% with placebo.”

Source: [Weir et al. (2026)](https://doi.org/10.1016/j.kint.2026.08.021)

<a id="topic-2.1.2.6.2-8"></a>

### Aldosterone, plasma renin activity, and aldosterone-renin ratio through week 48: Transform-HTN

| Biomarker | Percent change in geometric mean from Launch-HTN baseline at week 48 |
| --- | --- |
| Serum aldosterone | “-54.8%” |
| Plasma renin activity | “+123.9%” |
| Aldosterone-renin ratio | “-79.8%” |

Source: [Saxena et al. (2026b)](https://mineralystx.com/wp-content/uploads/2026/11/MV84448B5_AHA-SS2026-TRANSFORM-OLE-study-ORAL-Upload.pdf)

<a id="topic-2.1.2.6.2-9"></a>

### Circulating heart failure risk biomarkers: post hoc proteomic analysis of Launch-HTN and Advance-HTN

> “The PD analysis confirmed that lorundrostat was associated with significant increases in renin and decreases in angiotensinogen, reflecting target engagement of the renin-angiotensin-aldosterone system (RAAS). Lorundrostat was associated with significant reductions in 6 of 11 recently published candidate causal risk biomarkers of incident HF, including NT-proBNP, consistent with the hypothesis that RAAS inhibition favorably modulates processes involved in HF risk.”
> “This analysis characterized the systemic pharmacodynamic (PD) effects of lorundrostat and generated hypotheses regarding its potential modulation of pathways implicated in HF pathophysiology by profiling circulating protein biomarkers at baseline and after 12 weeks from 1,004 participants enrolled in the pivotal Phase 3 Launch-HTN and Phase 2b Advance-HTN trials.”

Source: [Mineralys Therapeutics press release, ENDO 2026 (2026)](https://ir.mineralystx.com/news-events/press-releases/detail/108/mineralys-therapeutics-presents-late-breaking-data-on)

<a id="topic-2.1.2.6.2-10"></a>

### Cardiac repolarization: concentration-QTc analysis in healthy participants

> “On the basis of this analysis, an effect on placebo-corrected ΔQTcF (ΔΔQTcF) >10 ms can be excluded within the observed range of plasma lorundrostat concentrations up to ~7800 ng/mL”
> “On the basis of the MAD results, an effect on ΔΔQTcF exceeding 10 ms can be excluded within the observed range of plasma lorundrostat concentrations up to ~6175 ng/mL”
> “There were no participants in the SAD and MAD studies with QTcF >450 ms or ΔQTcF >30 ms”
> “On the basis of these data, the regulatory requirement for a thorough QT study was waived”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

<a id="topic-2.1.2.6.2-11"></a>

### Cardiac ion channel and nonclinical cardiovascular safety

> “Lorundrostat was a weak inhibitor of hERG (mean [SEM] inhibition of 6.9% [2.5%] at 10 µM) with a half-maximal inhibitory concentration (IC50) of 95.4 µmol/L”
> “There were no statistically significant differences in blood pressure, QRS duration, QT interval, or QTc for lorundrostat up to 100 mg/kg versus placebo at any of the assessed time points”

Source: [Tortorici et al. (2024)](https://mineralystx.com/wp-content/uploads/2024/09/83964-ACCP-Poster-2024-09-03v2.pdf)

## Related pages
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Terms and abbreviations](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/terms-and-abbreviations.md)
- [Lorundrostat (MLS-101): Hypertension, in combination with other antihypertensive drugs](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/executive-summary.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Product information and disease description](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/product-information-and-disease-description.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Clinical evidence](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/clinical-evidence.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: Economic information and modeling report](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/economics.md)
- [Lorundrostat (MLS-101) in Hypertension, in combination with other antihypertensive drugs: References](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references) · [Markdown](https://www.evicenter.com/drugs/lorundrostat--hypertension-in-combination-with-other-antihypertensive-drugs/references.md)
